for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

H. Lundbeck A/S

LUN.CO

Latest Trade

221.80DKK

Change

-5.20(-2.29%)

Volume

255,993

Today's Range

221.80

 - 

226.30

52 Week Range

213.50

 - 

418.30

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
227.00
Open
226.30
Volume
255,993
3M AVG Volume
7.85
Today's High
226.30
Today's Low
221.80
52 Week High
418.30
52 Week Low
213.50
Shares Out (MIL)
198.77
Market Cap (MIL)
44,168.53
Forward P/E
13.91
Dividend (Yield %)
3.61

Next Event

Q3 2019 H Lundbeck A/S Earnings Release

Latest Developments

More

Lundbeck And Takeda Announce Trintellix Approval In Japan

Alder Biopharma Says If Co Terminates Lundbeck Deal To Enter Into A Superior Proposal, Co Will Be Required To Pay Termination Fee Of $87 Mln

Lundbeck To Acquire Alder Biopharmaceuticals

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About H. Lundbeck A/S

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Industry

Biotechnology & Drugs

Contact Info

Ottiliavej 9

+45.null.36301311

https://www.lundbeck.com/

Executive Leadership

Lars Soeren Rasmussen

Independent Chairman of the Board

Deborah L. Dunsire

President, Chief Executive Officer, Interim Executive Vice President Research & Development

Lene Skole

Deputy Chairman of the Board

Anders Goetzsche

Chief Financial Officer, Executive Vice President

Elise Hauge

Executive Vice President, People & Communication

Key Stats

2.88 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2016

15.6K

2017

17.2K

2018

18.1K

2019(E)

16.7K
EPS (DKK)

2016

6.140

2017

12.040

2018

19.660

2019(E)

15.941
Price To Earnings (TTM)
12.99
Price To Sales (TTM)
2.55
Price To Book (MRQ)
3.27
Price To Cash Flow (TTM)
9.64
Total Debt To Equity (MRQ)
4.82
LT Debt To Equity (MRQ)
3.65
Return on Investment (TTM)
23.45
Return on Equity (TTM)
15.51

Latest News

Latest News

Lundbeck buys Alder for $2 billion, eyes 'blockbuster' migraine therapy

Denmark's Lundbeck <LUN.CO> has agreed to buy Alder BioPharmaceuticals <ALDR.O> in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.

Lundbeck to buy migraine treatment developer Alder BioPharmaceuticals

Danish pharmaceutical company Lundbeck will acquire Alder BioPharmaceuticals in a deal valued at almost $2 billion, the company said in a statement on Monday.

Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.

UPDATE 1-Danish drugmaker Lundbeck lowers dividend range to fuel growth

* Posts quarterly operating profit below analyst expectations (Adds detail, background, more quotes and share price)

Drugmaker Lundbeck lowers dividend range to fuel growth

Danish drugmaker Lundbeck said on Tuesday it will lower dividends to shareholders as it seeks to invest more to make up for declining sales of older drugs.

UPDATE 1-Lundbeck shares slide as Danish drugmaker's new drugs disappoint

Shares in Lundbeck fell 5 percent on Wednesday after third-quarter sales of the Danish drugmaker's new drugs disappointed and it had to rely on its old line up to prop up revenues.

Drug maker Lundbeck raises 2018 financial guidance

Danish drug maker Lundbeck raised its full-year financial guidance on Wednesday citing "better-than-expected sales performance".

UPDATE 1-Lundbeck drops as its adjusted profit outlook fails to impress

Shares in Lundbeck dropped as much as 10 percent on Wednesday after the Danish drugmaker failed to impress the market with revisions to its full-year profit outlook.

Lundbeck Q2 beats forecast, lifts 2018 guidance

Danish drugmaker Lundbeck on Wednesday posted better than expected second quarter earnings and adjusted its full-year forecast to the upper end of the earlier guidance range.

Lundbeck looks to boost drug range with new CEO

Danish pharmaceutical company Lundbeck has picked Deborah Dunsire as its new chief executive after former CEO Kaare Schultz was poached by Teva last year.

Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million

Danish drugmaker Lundbeck <LUN.CO> said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.

Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln

Danish drugmaker Lundbeck said on Wednesday that it had reached a deal to pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.

BRIEF-H Lundbeck says FDA updates Trintellix label to include data showing improvement in processing speed

* REG-FDA UPDATES TRINTELLIX® (VORTIOXETINE) LABEL TO INCLUDE DATA SHOWING IMPROVEMENT IN PROCESSING SPEED, AN IMPORTANT ASPECT OF COGNITIVE FUNCTION IN ACUTE MAJOR DEPRESSIVE DISORDER (MDD)

BRIEF-Lundbeck Says New CEO To Be Named Within Six Months

* INTERIM CEO GOTZSCHE SAYS EXPECTS NEW CEO WILL BE NAMED WITHIN SIX MONTHS

UPDATE 1-Lundbeck's Q4 operating profit falls short of expectations

Danish drugmaker Lundbeck posted weaker than expected fourth quarter operating profit and gave a broad range for its 2018 financial guidance because of a range of uncertainties.

Lundbeck's Q4 operating profit below expectations

Drugmaker Lundbeck's fourth-quarter operating profit came in at 932 million Danish crowns ($155.19 million), undershooting the 1.05 billion expected by analysts in a Reuters poll.

BRIEF-H Lundbeck Enters Research Partnership On Treatment Of Schizophrenia

* LUNDBECK ENTERS RESEARCH PARTNERSHIP ON NOVEL TREATMENT OF SCHIZOPHRENIA

BRIEF-Lundbeck: Brintellix Approved In China

* LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Shares in Denmark's Lundbeck drop as sales of key drugs disappoint

Shares in Danish pharmaceutical firm Lundbeck fell as much as 6.8 percent on Tuesday as third-quarter sales of its newer drugs, such as those to treat bipolar disorder and depression, undershot market expectations.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up